}

Minapharm Pharmaceuticals shifts to standalone profits in Q1 2026

Updated 8/6/2026 12:01:00 PM
Minapharm Pharmaceuticals shifts to standalone profits in Q1 2026

Arab Finance: Minapharm Pharmaceuticals turned profitable in the first quarter (Q1) of 2026 with EGP 71.763 million in standalone profit, against standalone net losses of EGP 247.507 million in Q1 2025, according to the financial results.

Standalone earnings per share (EPS) hit EGP 5.72 at the end of March 2026, versus a loss per share of EGP 22.44 a year earlier.

Meanwhile, net sales increased to EGP 1.130 billion from EGP 1.005 billion.

Established in 1958, Minapharm Pharmaceuticals produces licensed and generic pharmaceuticals, vaccines, veterinary products, drug delivery systems, cosmetics, and skin care supplies.

The company's expertise covers a broad spectrum of medicines, ranging from small molecules to extremely complex bioengineered proteins.

 

Related News